EWTX Q1 2024 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$35M

Net Income

-$29M

EPS (Diluted)

$-0.33

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$554M

Total Liabilities

$19M

Stockholders' Equity

$535M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$35M	-$26M	-35.2%
Net Income	-$29M	-$23M	-24.9%